The multicenter, double-blind, placebo-controlled, randomized clinical trial included 56 children. The study subjects received 1.5 to 2.5 mg/kg of thalidomide or placebo once daily for eight weeks. The study found that a significantly higher number of children treated with thalidomide reached clinical remission, as opposed to the group treated with the placebo.
The researchers recommend replication of the study to confirm the clinical value of thalidomide.
More Articles on Gastroenterology:
AAAS Names Dr. Bishr Omary 2013 Fellow
4 Things to Know About Patient & Physician Shared Decision-Making in Gastroenterology
Study: Endoscopic Therapy vs. Surgery as Treatment for Early Esophageal Cancer
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
